Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing

• Status: Completed
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 4, randomized, double-blinded interventional trial comparing alternative doses of Acetazolamide for the prevention of High Altitude Illness.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Utah
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• 18 years or older

• English or Indian speaking

• Mountaineers or trekkers who plan to climb Mt. McKinley or trek to Base Camp on Mt. Everest

Exclusion Criteria:

• Low sodium and/potassium blood serum levels

• Kidney disease or dysfunction

• Liver disease, dysfunction, or cirrhosis

• Suprarenal gland failure or dysfunction

• Hyperchloremic acidosis

• Angle-closure glaucoma

• Taking high dose aspirin (over 325 mg/day)

• Any reaction to sulfa drugs or acetazolamide

• Pregnant or lactating women